Innovent

Innovent company information, Employees & Contact Information

Explore related pages

Related company profiles:

InnoVent has been using its internal resources and specialist partners to respond to the full range of issues linked to the development, construction and operation of wind and solar farms. With such knowledge, InnoVent is an experienced company that is well recognized in its field. InnoVent also has a long-term vision : InnoVent has chosen to export its know-how in solar farms and wind turbines to ten countries in Africa and has set up InnoSun, Innowind and InnoVent. InnoVent is investing its resources into research and development in new materials and in biogas, energy storage and wind turbines. Today, InnoVent commits to expand its activities in France and in Africa, operating and taking decisions independently. Together with the current projects we are busy with new ones that are to be developed in the next few months, while others are about to be commissioned.

Company Details

Employees
106
Founded
-
Address
5, Rue Horus, Villeneuve-D'ascq,hauts-De-France 59650,france
Phone
978-573-4204
Email
in****@****vent.de
Industry
Renewable Energy Power Generation
NAICS
Electric Power Generation
HQ
Villeneuve-d'Ascq, Hauts-de-France
Looking for a particular Innovent employee's phone or email?

Innovent Questions

News

Takeda signs deal worth up to $11.4bn with Innovent for cancer drug hopefuls - Pharmaceutical Technology

Takeda signs deal worth up to $11.4bn with Innovent for cancer drug hopefuls Pharmaceutical Technology

Takeda makes major bispecific, ADC pact with Innovent for $1.2B upfront - Endpoints News

Takeda makes major bispecific, ADC pact with Innovent for $1.2B upfront Endpoints News

Takeda pays Innovent $1.2B upfront, offers whopping $10B-plus in biobucks for cancer assets - Fierce Biotech

Takeda pays Innovent $1.2B upfront, offers whopping $10B-plus in biobucks for cancer assets Fierce Biotech

China’s Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion - WSJ - The Wall Street Journal

China’s Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion - WSJ The Wall Street Journal

Takeda Bets up to $11.4B for Three Innovent ADCs - BioSpace

Takeda Bets up to $11.4B for Three Innovent ADCs BioSpace

Innovent rings up $11.4B deal with Takeda for three I-O/ADC assets - BioWorld MedTech

Innovent rings up $11.4B deal with Takeda for three I-O/ADC assets BioWorld MedTech

Takeda inks $11.4 billion deal with Innovent for cancer drug candidates - Investing.com

Takeda inks $11.4 billion deal with Innovent for cancer drug candidates Investing.com

Innovent's weight-loss drug highlights China challenge for Novo, Lilly - Reuters

Innovent's weight-loss drug highlights China challenge for Novo, Lilly Reuters

Fierce Pharma Asia—Approvals for Innovent, Dizal; BMS partner's bispecific ADC readout - Fierce Pharma

Fierce Pharma Asia—Approvals for Innovent, Dizal; BMS partner's bispecific ADC readout Fierce Pharma

Roche strikes $1B deal with Innovent for DLL3-targeting ADC - FirstWord Pharma

Roche strikes $1B deal with Innovent for DLL3-targeting ADC FirstWord Pharma

Takeda inks $11.4 billion deal with Innovent for cancer drug candidates By Investing.com - Investing.com South Africa

Takeda inks $11.4 billion deal with Innovent for cancer drug candidates By Investing.com Investing.com South Africa

Standard Bank to fund InnoVent’s 44-MW Diaz wind project in Namibia - Renewables Now

Standard Bank to fund InnoVent’s 44-MW Diaz wind project in Namibia Renewables Now

With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs - Fierce Pharma

With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs Fierce Pharma

Bispecific cytokine delivers for Innovent at last | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Bispecific cytokine delivers for Innovent at last | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors - Business Wire

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors Business Wire

Takeda Boosts Pipeline and Revenue Growth Prospects With $1.2B Deal for Innovent Cancer Drugs - MedCity News

Takeda Boosts Pipeline and Revenue Growth Prospects With $1.2B Deal for Innovent Cancer Drugs MedCity News

New year, new $1B deal: Roche taps Innovent for new DLL3 ADC drug - BioWorld MedTech

New year, new $1B deal: Roche taps Innovent for new DLL3 ADC drug BioWorld MedTech

Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management - PR Newswire

Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management PR Newswire

Mankind Pharma inks pact with Innovent for immunotherapy drug in India - Business Standard

Mankind Pharma inks pact with Innovent for immunotherapy drug in India Business Standard

Analysis: Innovent's weight-loss drug highlights China challenge for Novo, Lilly - Yahoo Finance

Analysis: Innovent's weight-loss drug highlights China challenge for Novo, Lilly Yahoo Finance

Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions - GlobeNewswire

Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions GlobeNewswire

Mankind Pharma inks pact with Innovent for immunotherapy drug in India - Business Standard

Mankind Pharma inks pact with Innovent for immunotherapy drug in India Business Standard

Innovent wins China approval for obesity drug mazdutide - The Pharma Letter

Innovent wins China approval for obesity drug mazdutide The Pharma Letter

InnoVent gets N$1.9 billion for Diaz wind project - Windhoek Observer

InnoVent gets N$1.9 billion for Diaz wind project Windhoek Observer

Innovent Wins China Nod For Obesity Drug Rivaling Novo, Lilly - Bloomberg.com

Innovent Wins China Nod For Obesity Drug Rivaling Novo, Lilly Bloomberg.com

Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension - PR Newswire

Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension PR Newswire

Mankind Pharma and Innovent partner for Sintilimab commercialisation in India - Pharmaceutical Technology

Mankind Pharma and Innovent partner for Sintilimab commercialisation in India Pharmaceutical Technology

Chinese drug start-ups poised for 2025 profits, in industry milestone - South China Morning Post

Chinese drug start-ups poised for 2025 profits, in industry milestone South China Morning Post

Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity - PR Newswire

Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity PR Newswire

Innovent Biologics secures 2nd NDA approval for lung cancer drug as 1st-line treatment - Mugglehead Magazine

Innovent Biologics secures 2nd NDA approval for lung cancer drug as 1st-line treatment Mugglehead Magazine

Coherus Biosciences Terminates Deal With Innovent for Avastin Biosimilar - Center for Biosimilars

Coherus Biosciences Terminates Deal With Innovent for Avastin Biosimilar Center for Biosimilars

Innovent gets IND for oral GLP-1 agonist - BioWorld MedTech

Innovent gets IND for oral GLP-1 agonist BioWorld MedTech

Mankind Pharma and Innovent partner for sintilimab - The Pharma Letter

Mankind Pharma and Innovent partner for sintilimab The Pharma Letter

First-in-Class Dual-Action Cancer Drug: Innovent's IBI363 Heads to Global Phase 3 Trial for Resistant Lung Cancer - Stock Titan

First-in-Class Dual-Action Cancer Drug: Innovent's IBI363 Heads to Global Phase 3 Trial for Resistant Lung Cancer Stock Titan

Innovent bags another phase 3 win in China for next-gen Lilly GLP-1 drug - Fierce Biotech

Innovent bags another phase 3 win in China for next-gen Lilly GLP-1 drug Fierce Biotech

Lummus and InnoVent Renewables sign MoU for tire pyrolysis technology - Tire Technology International Magazine

Lummus and InnoVent Renewables sign MoU for tire pyrolysis technology Tire Technology International Magazine

Innovent inks $11.4 billion cancer drug partnership with Japan's Takeda - MSN

Innovent inks $11.4 billion cancer drug partnership with Japan's Takeda MSN

World's First Dual GCG/GLP-1 Drug Shows 87.4% Success Rate: Innovent's Mazdutide Approved in China - Stock Titan

World's First Dual GCG/GLP-1 Drug Shows 87.4% Success Rate: Innovent's Mazdutide Approved in China Stock Titan

Takeda, Innovent Ink $11.4 Billion Cancer Drug Deal - Businesskorea

Takeda, Innovent Ink $11.4 Billion Cancer Drug Deal Businesskorea

Eli Lilly, Innovent hit with FDA rejection for China-developed lung cancer drug after tough review - Fierce Pharma

Eli Lilly, Innovent hit with FDA rejection for China-developed lung cancer drug after tough review Fierce Pharma

FDA rejects Lilly and Innovent immunotherapy, sending signal to drugmakers - BioPharma Dive

FDA rejects Lilly and Innovent immunotherapy, sending signal to drugmakers BioPharma Dive

Roche Kicks Off 2025 Committing a Potential $1B for Another ADC From China - BioSpace

Roche Kicks Off 2025 Committing a Potential $1B for Another ADC From China BioSpace

Innovent Bio hopes for plus-sized profits from obesity drug - thebambooworks.com

Innovent Bio hopes for plus-sized profits from obesity drug thebambooworks.com

Eli Lilly Strikes $1 Billion Deal with Innovent for Checkpoint Inhibitor - BioSpace

Eli Lilly Strikes $1 Billion Deal with Innovent for Checkpoint Inhibitor BioSpace

Thumbs down on Lilly, Innovent China trial for lung cancer drug Tyvyt, says FDA AdComm - Fierce Pharma

Thumbs down on Lilly, Innovent China trial for lung cancer drug Tyvyt, says FDA AdComm Fierce Pharma

Innovent starts phase II trial for ipilimumab copy biological - Generics and Biosimilars Initiative

Innovent starts phase II trial for ipilimumab copy biological Generics and Biosimilars Initiative

Roche pens $2B biobucks pact with Innovent Biologics for bispecific and cell therapies - Fierce Biotech

Roche pens $2B biobucks pact with Innovent Biologics for bispecific and cell therapies Fierce Biotech

Amagma Therapeutics Announces Strategic Partnership with Innovent Biologics in Inflammatory Diseases - Business Wire

Amagma Therapeutics Announces Strategic Partnership with Innovent Biologics in Inflammatory Diseases Business Wire

Tata Technologies launches InnoVent for Engineering Students, register – Sights In Plus - Tata Technologies

Tata Technologies launches InnoVent for Engineering Students, register – Sights In Plus Tata Technologies

Innovent buys Chinese rights to Incyte drugs for $40M upfront - Fierce Biotech

Innovent buys Chinese rights to Incyte drugs for $40M upfront Fierce Biotech

Tata Technologies Partners with AWS for Third InnoVent Hackathon - Autocar Professional

Tata Technologies Partners with AWS for Third InnoVent Hackathon Autocar Professional

Test your metal: ExOne’s Innovent 3D printer for materials R&D - develop3d

Test your metal: ExOne’s Innovent 3D printer for materials R&D develop3d

Takeda Bets up to $11.4B for Up To Three Innovent Cancer Assets - NewsBreak: Local News & Alerts

Takeda Bets up to $11.4B for Up To Three Innovent Cancer Assets NewsBreak: Local News & Alerts

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant